gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SCYXHealthcarePharmaceuticals

SCYNEXIS, Inc. (SCYX)

$3.84−2.54%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.84▼ 23.82% in range
Nov 4, 2025Low $3.57 · High $45.12Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

SCYNEXIS closed at $3.84 on Nov 4, down 2.54%, 91.5% below its 52-week closing high. Volume of 22.4K shares was 0.25× its 20-day average (below normal).

Split-adjusted performance: -20.7% over one month, -51.1% over six months, -24.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $235K, down 82.8% from a year earlier, with a net margin of 3147.7%.

Short interest was 420.5K shares at the Oct 15 settlement, down 29.2% from the prior report (4.7% of float, 2.3 days to cover).

Market cap$38.2M9.9M shares
Revenue · quarter$235.0K−82.8% YoY
Diluted EPS$0.63—
P/E · TTM—P/S 2.0×
Net margin3,147.7%Gross 100.0%
Dividend yieldNone
52-week range3.57 – 45.12−91.5% from high
Volume22.4K0.25× 20-day avg
Volatility · 60d63.6%Annualised
Short % of float4.7%2.3 days to cover
Net cash$54.1MCash $54.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.8%1M −20.7%3M −26.2%6M −51.1%YTD −24.1%1Y −24.8%3Y −72.3%5Y −90.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum24
Revenue growth15
Net margin100
Value (low P/E)—
Size28

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short420.5K−29.2% vs prior
Days to cover2.3Settled Oct 15
% of float4.7%
Short vol. 10d61.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SCYXSCYNEXIS$3.84−2.54%−51.1%−82.8%3147.7%—$38.2M
GRCEGrace Therapeutics$1.81−1.63%−23.6%———$38.1MCompare
VERUVeru$2.20+1.85%−0.9%———$37.5MCompare
ALDXAldeyra Therapeutics$0.6474+4.32%−62.8%———$39.1MCompare
DWTXDogwood Therapeutics$1.03−0.96%−37.6%———$39.4MCompare
BTMDBiote$1.23+9.82%−44.1%−9.5%−14.8%6.0$35.3MCompare
NNVCNanoViricides$1.38−3.50%−5.5%———$35.2MCompare
IBOImpact BioMedical$4.10+1.99%−48.8%−57.1%−23300.0%44.4$35.0MCompare
ELTXElicio Therapeutics$1.56+2.63%−85.1%———$42.3MCompare

News about SCYNEXIS

All news →
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal DiseasesGlobeNewswire Inc. · Oct 22, 2026▲ PositiveSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 7, 2026NeutralSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Benzinga · Mar 31, 2026▲ Positive

Quick answers

What does SCYNEXIS do?
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
What is SCYX's market cap?
$38.21M, based on the Nov 4 close of $3.84.
Does SCYNEXIS pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SCYX is sold short?
420.5K shares, 4.7% of float, as of Oct 15, 2026.
What sector is SCYX in?
Healthcare, in the Pharmaceuticals industry.

About SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

HQ: Jersey City, NJ29 employeesListed May 2, 2014scynexis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology